How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,836 results for

Wart Treatment

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Topical NVN1000 for the Treatment of External Genital and Perianal Warts Topical NVN1000 for the Treatment of External Genital and Perianal Warts - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical (...) NVN1000 for the Treatment of External Genital and Perianal Warts The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02462187 Recruitment Status : Completed First Posted : June 3, 2015 Last Update Posted : October 15, 2018 Sponsor: Novan, Inc. Collaborator: PPD Information provided by (Responsible Party

2015 Clinical Trials

142. ALC-919 For The Treatment Of Common Warts

ALC-919 For The Treatment Of Common Warts ALC-919 For The Treatment Of Common Warts - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. ALC-919 For The Treatment Of Common Warts The safety and scientific (...) , randomized, double blind, vehicle-controlled phase 2 study of subjects 8 years of age and older with Common Warts (Verruca vulgaris) who desire treatment. Condition or disease Intervention/treatment Phase Verruca Vulgaris Drug: 2014-ALC-919-US Drug: Vehicle-Control Topical Solution Phase 2 Detailed Description: This is a single-center, randomized, double blind, vehicle-controlled phase-2 study of subjects 8 years of age and older with Common Warts (Verruca vulgaris) who desire treatment. A total of four

2015 Clinical Trials

143. Topical adapalene in the treatment of plantar warts; randomized comparative open trial in comparison with cryo-therapy. Full Text available with Trip Pro

Topical adapalene in the treatment of plantar warts; randomized comparative open trial in comparison with cryo-therapy. Various therapeutic modalities, which are available for treating plantar wart, have not been successful every time.To evaluate topical adapalene under occlusion in the treatment of plantar warts and compare it with cryo-therapy.50 patients with 424 plantar warts were included in this single center, two arm, prospective, randomized, control, open study. Patients were allocated (...) except one treated by cryo-therapy cleared in 52.17 ± 30.06 (82.23-22.11) days. There were no side effects like scar formation, irritation, erythema, or infections with adapalene group while in the cryo group scar was seen in 2 patients, pain in 24, erythema in 10, and infection in 3 patients.Adapalene gel 0.1% under occlusion is an effective, safe and easy to use treatment for plantar warts and may help clear lesions faster than cryo-therapy.

2015 Indian journal of dermatology Controlled trial quality: uncertain

144. Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02377999 Recruitment Status : Completed First Posted : March 4, 2015 Last Update Posted : May 3, 2017 Sponsor: LEO Pharma Information

2015 Clinical Trials

145. A single-blinded randomized controlled study to assess the efficacy of twice daily application of sinecatechins 15% ointment when used sequentially with cryotherapy in the treatment of external genital warts. (Abstract)

A single-blinded randomized controlled study to assess the efficacy of twice daily application of sinecatechins 15% ointment when used sequentially with cryotherapy in the treatment of external genital warts. To evaluate the efficacy of sequential therapy of cryotherapy and sinecatechins 15% ointment BID versus cryotherapy alone in treatment of external genital warts (EGW).Forty-two subjects with at least two EGW lesions underwent cryotherapy to all lesions. One week following cryotherapy (...) , subjects were randomized 1:1 to receive either no additional treatment or treatment with sinecatechins 15% ointment BID up to 16 weeks or until complete clearance. The total number of visible baseline and new EGW were recorded at each visit. Subjects were followed for a total of 65 weeks post-treatment.There was a significant reduction in mean number of lesions from baseline after 16 weeks of treatment in the cryotherapy-sinecatechins ointment group compared to cryotherapy alone (-5.0 lesions vs -2.1

2015 Journal of drugs in dermatology : JDD Controlled trial quality: uncertain

146. Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study. (Abstract)

Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study. Intralesional purified protein derivative (PPD) or mumps, measles, rubella (MMR) were not previously compared regarding their efficacy or mechanism of action in treatment of warts. We aimed to compare their efficacy in treatment of multiple warts and investigate their effect on serum interleukin (IL)-4 and IL-12. Thirty patients (...) with multiple warts were included (10 treated with PPD, 10 with MMR, and 10 with normal saline (control)). Injection was done every 3 weeks until clearance or maximum of three treatments. Clinical response of target and distant warts was evaluated. Serum ILs-4 and -12 were assessed before and after treatment. A significantly higher rate of complete response was found in target and distant warts with PPD (60% each) and MMR (80%, 40%, respectively) compared with controls (0%), with no significant difference

2015 Dermatologic therapy Controlled trial quality: uncertain

147. Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.

Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population. Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02567149 Recruitment Status : Withdrawn (No funding) First Posted : October

2015 Clinical Trials

148. Nanopulse Efficacy Study for the Treatment of Common Warts

Nanopulse Efficacy Study for the Treatment of Common Warts Nanopulse Efficacy Study for the Treatment of Common Warts - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Nanopulse Efficacy Study (...) for the Treatment of Common Warts The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02650466 Recruitment Status : Completed First Posted : January 8, 2016 Last Update Posted : March 29, 2017 Sponsor: University of Southern California Information provided by (Responsible Party): Stefani Takahashi, University

2015 Clinical Trials

149. Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02393417 Recruitment Status : Completed First Posted : March 19, 2015 Last Update Posted : April 17, 2018

2015 Clinical Trials

150. Quadrivalent Human Papillomavirus Vaccination: A Promising Treatment for Recalcitrant Cutaneous Warts in Children. Full Text available with Trip Pro

Quadrivalent Human Papillomavirus Vaccination: A Promising Treatment for Recalcitrant Cutaneous Warts in Children. 25824471 2016 08 12 2015 11 04 1651-2057 95 8 2015 Nov Acta dermato-venereologica Acta Derm. Venereol. Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children. 1017-9 10.2340/00015555-2111 Abeck Dietrich D Group practice for Dermatology and Allergology, , Munich, Germany. professorabeck@mytum.de. Fölster-Holst Regina R eng (...) Journal Article Sweden Acta Derm Venereol 0370310 0001-5555 0 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 IM Child Female Foot Dermatoses drug therapy Hand Dermatoses drug therapy Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 therapeutic use Humans Male Retreatment Warts drug therapy 2015 4 1 6 0 2015 4 1 6 0 2016 8 16 6 0 ppublish 25824471 10.2340/00015555-2111

2015 Acta Dermato-Venereologica

151. Plantar Wart

(pared) Painless on lateral pressure Retain normal fingerprint lines (warts do not) Contrast with pinpoint blood vessels of Plantar Warts Foreign body reaction (sheering in sports) Epithioma cuniculatum (verrucous carcinoma) IX. Precautions No treatment needed if asymptomatic Avoid aggressive technique Surgical excision X. Management ral Topical treatments require 2-3 months for eradication Relieve pressure on wart area with pads Soak foot before application of salicylic acid Soak in warm water (...) years without treatment Recurrence after treatment is common XIII. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Plantar Wart." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Plantar wart (C0042548) Definition (NCI) A wart in the plantar surface of the foot. It is caused by human papillomavirus. Concepts Disease or Syndrome ( T047

2018 FP Notebook

152. Genital Wart

-related malignancy See prognosis below VIII. Management: Overall treatment strategy Non-Keratinized Warts First line: or Alternative: Refractory: , TCA, ablation Keratinized warts First line Warts <10 mm: Warts >10 mm: Surgical excision (or if persistent) Adjunctive: applied as pretreatment Warts on mucosal surface (Vagina, , anal) First line: Alternative: Trichloroacetic Acid Pregnancy Indications for HPV treatment in pregnancy Treat only lesions that would obstruct labor or result in significant (...) Solution is left on skin for 1-4 hours and then washed off Similar clearance rates and recurrence to self applied agents listed above FDA category X Toxicity risk (deaths have occurred) Limit application area to <10 cm^2 Limit amount applied to <0.5 ml per treatment Trichloroacetic acid (TCA) 60-90% compounded solution (or Bichloroacetic Acetic Acid or BCA) Apply to each wart up to three times weekly until resolution Allow to dry (lesion will "frost" or turn white) Solution is liquidy and easily

2018 FP Notebook

153. Wart Immune Therapy

: Wart Immune Therapy , Intralesional Candida Injection From Related Chapters II. Indication s refractory to other treatments Not FDA approved (anecdotal support only) III. Preparation Killed Candida (Monilia albicans) Used in Manitou control (1:1000 solution) IV. Application Preparation Mix equal parts of 1% without Use 30 gauge needle Choose largest wart Injection Inject 0.1 cc to 0.3 cc intradermal beside wart Wart should blanche with injection V. Precautions Wear protective glasses Limit to 3 (...) Wart Immune Therapy Wart Immune Therapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Wart Immune Therapy Wart Immune Therapy Aka

2018 FP Notebook

154. Trends in genital warts due to the quadrivalent human papillomavirus vaccination: a meta-analysis

Trends in genital warts due to the quadrivalent human papillomavirus vaccination: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address (...) is the typical model of choice for pre-clinical meta-analyses. This is because in the fixed-effect model, it is assumed that the differences in observed effect between studies is solely due to sampling error (i.e. differences in sample size), and that the true effect is the same (fixed) across all studies. However, this assumption is unlikely to hold true for data from animal studies, which generally include various species, strains and treatment regimes, for which different true effects are likely to exist

2018 PROSPERO

155. Impact and effectiveness of the human papillomavirus (HPV) vaccine on anogenital warts in United States and Canada: a systematic review

Impact and effectiveness of the human papillomavirus (HPV) vaccine on anogenital warts in United States and Canada: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne (...) . ">Effect measure The random-effects model is the typical model of choice for pre-clinical meta-analyses. This is because in the fixed-effect model, it is assumed that the differences in observed effect between studies is solely due to sampling error (i.e. differences in sample size), and that the true effect is the same (fixed) across all studies. However, this assumption is unlikely to hold true for data from animal studies, which generally include various species, strains and treatment regimes

2018 PROSPERO

156. Warts - anogenital: Scenario: Management

. Screening for co-existing sexually transmitted infections (STIs) is essential, particularly in people younger than 25 years of age and those with other genital symptoms. Perform a vaginal speculum examination in women. Perform proctoscopy (where available), if there is a history of anal receptive sex. Tracing of previous sexual partner(s) is not recommended for people with anogenital warts in the absence of other STIs. Only offer treatment for anogenital warts in primary care if: Referral to a sexual (...) health specialist is not possible (because it is declined or unavailable) and the diagnosis of external genital warts can be confidently made. The skills and resources to provide comprehensive assessment and treatment, as well as screening and contact tracing for other sexually transmitted infections are available. For more information, see the section on . Provide information and about anogenital warts. where appropriate. the person if required. What treatments are available for anogenital warts

2016 NICE Clinical Knowledge Summaries

157. Warts - anogenital

malignancy. Anogenital condylomata lata of secondary syphilis. Referral to a sexual health specialist is recommended for all people with anogenital warts, especially: Women who are pregnant. Children (the possibility of sexual abuse should be considered). People who are immunocompromised (for example HIV). Referral is essential if: The diagnosis is uncertain. Malignancy or intraepithelial neoplasia is suspected. The warts are cervical, intrameatal, or intra-anal. Treatment for anogenital warts should (...) only be offered in primary care if: Referral to a sexual health specialist is declined or unavailable and the diagnosis of external genital warts is certain. The skills and resources to provide a comprehensive sexual health service are available. Treatment options for anogenital warts include: No treatment — one-third of visible warts disappear spontaneously within 6 months. Self-applied treatments (podophyllotoxin 0.5% solution, or 0.15% cream, imiquimod 5% cream, sinecatechins 10% ointment

2016 NICE Clinical Knowledge Summaries

158. Bismuth Injections in the Treatment of Warts: Report of Bismuth Injections in the Treatment of Sixty-One Cases of Warts at the Cowell Memorial Hospital of the University of California Full Text available with Trip Pro

Bismuth Injections in the Treatment of Warts: Report of Bismuth Injections in the Treatment of Sixty-One Cases of Warts at the Cowell Memorial Hospital of the University of California 18742710 2008 08 29 2008 11 20 0093-4038 39 6 1933 Dec California and western medicine Cal West Med Bismuth Injections in the Treatment of Warts: Report of Bismuth Injections in the Treatment of Sixty-One Cases of Warts at the Cowell Memorial Hospital of the University of California. 385-8 Lunsford C J CJ Thomson

1933 California and western medicine

159. Treatment of external genital warts and pre-invasive neoplasia of the lower tract. In: Canadian consensus guidelines on human papillomavirus.

Treatment of external genital warts and pre-invasive neoplasia of the lower tract. In: Canadian consensus guidelines on human papillomavirus. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research

2009 Society of Obstetricians and Gynaecologists of Canada

160. Interferon for the treatment of genital warts: a systematic review

Interferon for the treatment of genital warts: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>